Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”

作者：Baoqing Chen, Z. Li, Xingyuan Cheng, Mian Xi · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco-26-01677 · 研究领域：Medicine、Oncology、Internal medicine、Cancer research、Immunology